Results 181 to 190 of about 2,925,762 (288)

De novo design of protein condensation inhibitors by targeting an allosteric site of cGAS. [PDF]

open access: yesNat Commun
Zhao W   +16 more
europepmc   +1 more source

MDL‐800‐induced SIRT6 activation decreases age‐associated osteoarthritis in mice

open access: yesArthritis &Rheumatology, Accepted Article.
Objective SIRT6 is a nuclear‐localized histone deacetylase that regulates multiple pathways associated with aging. This study aimed to determine whether systemic administration of a small molecule activator of SIRT6, MDL‐800, decreases the severity of age‐associated osteoarthritis (OA) in mice.
Matheus Moreira Perez   +13 more
wiley   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

Identification of a Novel Allosteric Site at the M<sub>5</sub> Muscarinic Acetylcholine Receptor. [PDF]

open access: yesACS Chem Neurosci, 2021
Burger WAC   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy